CT83 Antibody

Datasheet

Code	CSB-PA711093ZA01HU
Size	Enquire
Have Questions?	Leave a Message or Start an on-line Chat

Product Details
Related Products
Customer Reviews and Q&A
Target Background

Product Details

Full Product Name

Rabbit anti-Homo sapiens (Human) CT83 Polyclonal antibody

Uniprot No.

Q5H943

Target Names

CT83

Alternative Names

CT83 antibody; CXorf61 antibody; KKLC1 antibody; Kita-kyushu lung cancer antigen 1 antibody; KK-LC-1 antibody; Cancer/testis antigen 83 antibody

Raised in

Rabbit

Species Reactivity

Homo sapiens

Immunogen

Recombinant Homo sapiens CT83 protein

Immunogen Species

Homo sapiens (Human)

Conjugate

Non-conjugated

Clonality

Polyclonal

Isotype

IgG

Purification Method

Antigen Affinity Purified

Concentration

It differs from different batches. Please contact us to confirm it.

Buffer

Preservative: 0.03% Proclin 300
Constituents: 50% Glycerol, 0.01M PBS, pH 7.4

Form

Liquid

Tested Applications

ELISA, WB (ensure identification of antigen)

Protocols

ELISA Protocol

Troubleshooting and FAQs

Antibody FAQs

Storage

Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.

Value-added Deliverables

① 200ug * antigen (positive control);
② 1ml * Pre-immune serum (negative control);

Quality Guarantee

① Antibody purity can be guaranteed above 90% by SDS-PAGE detection;
② ELISA titer can be guaranteed 1: 64,000;
③ WB validation with antigen can be guaranteed positive;

Lead Time

Made-to-order (12-14 weeks)

Usage

For Research Use Only. Not for use in diagnostic or therapeutic procedures.

Customer Reviews and Q&A

■ Customer Reviews

There are currently no reviews for this product.

Submit a Review here

Target Background

Gene References into Functions

High KK-LC-1 expression was detected in breast cancer, especially in oestrogen receptor-negative subtypes. PMID: 30275220
The KK-LC-1 expression rate was high even in patients with stage I cancer, suggesting that KK-LC-1 is a useful biomarker for early diagnosis of gastric cancer. PMID: 29290656
KK-LC-1 was frequently expressed in gastric cancer caused by H. pylori infection. PMID: 28438869
CXorf61 is a target for T cell based immunotherapy of triple-negative breast cancer. PMID: 26327325
The frequency of KK-LC-1 expression was higher than that of the other CTAs. KK-LC-1 might be a useful target for immunotherapy and in diagnosis of gastric cancer. PMID: 26026129

Hide All

Subcellular Location

Cell membrane; Single-pass type II membrane protein.

Tissue Specificity

Specifically expressed in testis. Expressed by cancer cell lines.

Database Links

HGNC: 33494

OMIM: 300625

KEGG: hsa:203413

STRING: 9606.ENSP00000360961

UniGene: Hs.97892

Promotions

Email: [email protected]
Distributors Worldwide

Service

Phage Display Service

Antibody Service

Protein Service

Gene Synthesis Service

Oligo Synthesis Service

CT83/KK-LC-1: a Promising Therapeutic Target of CTAs Family, Currently in Clinical Research for Breast, Lung, Gastric Cancers, and Beyond! Antibody FAQs What Is an Antibody? How to Choose an Antibody for Scientific Research? The difference between primary antibody and secondary antibod The Meaning of Irregular Antibody Screening Tag Antibodies, Your Good Partner in Protein Research How to Choose the Loading Control Antibodies?

Related pathways

Target Therapy

Call us

301-363-4651 (Available 9 a.m. to 5 p.m. CST from Monday to Friday)

[email protected]

Address

7505 Fannin St., Ste 610, Room 7 (CUBIO Innovation Center), Houston, TX 77054, USA

Join us with

Subscribe newsletter

Leave a message

Message

Product >> Product Name：
Product >> Code：
Name： *
Email： *
Company/Organization：
Phone：
Since emails may get flagged by spam filters occasionally, we recommend leaving your phone number as a precaution. Your information is safe with us.
Question/Comment： *
Your Region： *
I'd like to receive email newsletters from Cusabio

Yes

No
How do you know CUSABIO?

Email

Distributor

Search engine

Advertisement

Others
CAPTCHA verification：

CT83 Antibody

Product Details

Related Products

Customer Reviews and Q&A

Target Background